Skip to Content

Aeterna Zentaris to Present Poster on Novel Oral Anticancer Erk Inhibitors at Upcoming American Chemical Society's National Meeting

QUÉBEC CITY, Aug. 23, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Director Medicinal Chemistry, Matthias Gerlach Ph.D., will present a poster on novel orally active anticancer Erk inhibitors, at the upcoming 242nd American Chemical Society's National Meeting to be held August 28 through September 1, 2011 at the Colorado Convention Center in Denver, Colorado.

The poster #17068 titled, "N ovel Pyrido[2,3-b]pyrazines as orally active ERK inhibitors", M. Gerlach, I. Seipelt, G. Mueller, T. Schuster, L. Blumenstein, B. Aicher, E. Guenther and M. Teifel, will be presented during the two following sessions:

Date and time:
Poster Session ID:
Venue:  Monday, August 29, 2011, 8 p.m. - 10 p.m. (Mountain Time)
Sci-Mix (Division of Medicinal Chemistry)
Hall D, Colorado Convention Center 
Date and time:
Poster Session ID:
Venue:  Wednesday, August 31, 2011, 7 p.m. - 11 p.m. (Mountain Time)
General Poster session (Division of Medicinal Chemistry)
Four Seasons Ballroom, Colorado Convention Center 

About Erk 1/2 Inhibitor Compounds

Extracellular signal-regulated kinases ("Erks") act in the Ras-Raf-Mek-Erk signaling cascade and regulate various cellular processes such as cell growth, proliferation and survival in response to a variety of extracellular or intrinsically mutated upstream signals. Aeterna Zentaris has identified small molecular compounds that selectively inhibit Erk1/2, among them, AEZS-131, which has shown to significantly inhibit tumor growth in in vivo studies. Early development of the Erk inhibitor AEZS-131 is an integral part of Aeterna Zentaris' kinase research program comprising the investigation of different compounds for single Erk inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit





Investor Relations

Ginette Beaudet Vallieres
Investor Relations Coordinator
(418) 652-8525 ext. 265

Media Relations

Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406

Posted: August 2011